News

The study, IMPOWER 22, will evaluate the efficacy and safety of islatravir — Merck’s novel investigational nucleoside reverse transcriptase translocation inhibitor (NRTTI) under evaluation for both treatment and

“There is a critical unmet need for people living with Wolfram syndrome, a rare genetic disease in which many patients die prematurely with severe neurological disabilities,” said Wolfram

The independent and NIH-appointed Data Safety Monitoring Board (DSMB) revealed that the mRNA-1273 candidate has demonstrated an efficacy rate of 94.5% in the first interim analysis of the

The phase 2 segment will evaluate the efficacy of Covid-19 DNA vaccine candidate called INO-4800 in adults in the US. Inovio’s study will be financed by the US

Dr. Himanshu Pop Hale, Ace Hospital Pune, India, has recruited the first patient in the IPF phase II Proof-of-Concept study with C21 (VP01 project). “We are pleased to announce that

As part of single target research collaboration, both companies will conduct research activities to select a pre-clinical candidate after which Roche will focus on further development and global

The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target date of June 30, 2021. Trichomoniasis vaginalis is the most common non-viral, curable sexually transmitted infection

Keytruda (pembrolizumab), an anti-PD-1 therapy, works by enhancing the ability of the body’s immune system to identify and fight tumour cells. It is a humanised monoclonal antibody that

The addition of Calquence to best supportive care (BSC) has failed to increase the proportion of patients who remained alive and free of respiratory failure. Calquence, the next-generation